Merlin Biomedical

Merlin Biomedical (Xiamen) Co, Ltd. located in National Biomedical Industrial Zone, Xiamen,founded on Jan 23rd, 2017. Merlin advanced talents team as the core, with clean workshop and complete equipment, perfect quality management system for the two wings, with pioneering spirit, innovation, to form a high-tech enterprises integrated with research and development, production and sales. Merlin main business covers in vitro diagnostic reagents and devices, including molecular diagnosis, immunodiagnosis and biochemical reagents three series. Detection Kit of 4 Respiratory Pathogens Nucleic Acid can be used for nucleic acid detection of SARS-CoV-2, Influenza A Virus (FluA), Influenza B Virus (FluB) and Respiratory syncytial virus (RSV). Detection Kit of 5 Urogenital Tract Pathogens Nucleic Acid can be used for the auxiliary diagnosis of Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Ureaplasma urealyticum (UU), Mycoplasma hominis (MH) and Mycoplasma genitalium (MG). Genetic testing has become a new trend in the market to guide individualized drug use. Merlin has developed more than 20 general gene sequencing kits, which can be used to guide individualized accurate drug use for people with high blood pressure and hyperlipidemia. Single Use Specimen Container and DNA/RNA Extraction Kit sell well in domestic and abroad, widely recognized. Merlin has made great achievements in the field of reagents, broken through technical barriers in the field of devices, and developed NAP-Fluo Cycler, MagXtractor Automatic Nucleic Acid Extractor and EaseMS Therapeutic Drug Monitoring System. A number of patents were born simultaneously in the development of these devices, protecting the technology. Reagent and instrument develop synchronously, complement each other, and create the strongest competitiveness and vigorous development force for the company in the market.